Molecular Diagnostic Companies
.png)
Published: September 2025
Molecular diagnostic solutions are advanced techniques and tools used to analyze biological markers in the genome and proteome of the individual’s genetic code. These diagnostic solutions being offered by molecular diagnostic companies are essential for detecting and monitoring diseases, identifying genetic predispositions, and guiding the patients for personalized treatment plans. The core technologies include polymerase chain reaction, next-generation sequencing and microarrays. Molecular diagnostic solutions are pivotal across various medical fields, including oncological disorders, infectious diseases, genetic testing, and personalized medicines. These solutions enhance the accuracy of diagnoses, enable and support tailored treatment strategies aiming to ultimately improve diagnostic outcomes and improve public health.
Molecular diagnostics aid in early detection of diseases by utilizing the genetic information of a patient in order to facilitate therapeutic monitoring and improve the overall patient healthcare outcome. Driven by the increasing demand for precision medicine and point-of-care diagnosis, the molecular diagnostic companies have gained significant traction in the last few years. Further, integration of artificial intelligence (AI) and machine learning tools can enable organizations to process a vast amount of genomic data, identify patterns and make diagnostic decisions with informed accuracy. AI-driven tools can tailor diagnostics and treatments to individual patient requirements by integrating genetic, proteomic, and clinical data. It is worth noting that that ongoing improvements in next-generation sequencing have made such services more affordable, facilitating their widespread adoption in clinical settings. Moreover, technologies, such as long-read sequencing aims to improve the accuracy of genome assembly and identification of structural variants. On the other hand, molecular diagnostic companies are also advancing single cell sequencing, enabling detailed analysis of individual cells, providing insights into cellular heterogeneity and disease mechanisms.
Roots Analysis has conducted an exhaustive study on Molecular Diagnostics Market featuring the current market landscape and future opportunity for the companies engaged in the domain of molecular diagnostics, over a span of 10 years.
Table of Contents
Below, we have listed (based on geography), the top 10 molecular diagnostic companies.
- Abbott
- Agilent Technologies
- BD
- Danaher
- Thermo Fisher Scientific
- bioMérieux
- Grifols
- Roche
- Siemens Healthineers
- Sysmex
Discover Below the Details on Top 10 Molecular Diagnostic Companies
Let us deep dive to understand the activity of the 10 top molecular diagnostic companies engaged in providing services and products related to molecular diagnosis. It is essential to note that the selection of top players can differ substantially according to the defined criteria.
Abbott’s Alinity m, a molecular diagnostic analyzer, Utilizes Innovative Technology to Deliver a New Level of Flexibility and Efficiency as Fully Integrated and Automated Systems
- Abbott
Abbott is engaged in providing advanced diagnostic solutions, catering to the needs of both medical professionals and consumers. The company’s portfolio includes a broad range of diagnostic equipment, nutritional products and pharmaceuticals. Abbott's presence spans across North America, Europe, and Africa, with over 100 production sites in more than 30 countries. The company claims to offer a variety of molecular diagnostic solutions which can be used to detect / diagnose a number of disease conditions.
Abbott: Company Overview
| Key Parameters |
Specifications |
| Company Logo |  |
| Year of Establishment | 1888 |
| Number of Employees | 10,000+ |
| Headquarters |  |
Some of the molecular diagnostic solutions offered by Abbott have been mentioned below:
Abbott: Product Portfolio
`
| S. No. | Product Name | Solution Type | Technology | Diagnostic Applications |
| 1 | Alinity m | Molecular Diagnostics Analyzer | Real-time PCR | Infectious Diseases, STIs / STDs |
| 2 | AneuVysion Kit | Multicolor DNA Probe Kit | FISH | Genetic Diseases |
| 3 | m2000 Realtime System | PCR Testing Automation System | PCR | Infectious Diseases, STIs / STDs |
| 4 | RealTime HBV | Viral Load Assay | PCR | Hepatic Diseases |
| 5 | RealTime High-Risk HPV | Viral Load Assay | PCR | Infectious Diseases |
| 6 | UroVysion Kit | Urine-based Molecular Test | FISH | Oncological Disorders |
| 7 | Vysis ALK Kit | Probe Kit | FISH | Oncological Disorders |
| 8 | Vysis CEP 12 Kit | DNA Probe Kit | FISH | Oncological Disorders |
| 9 | Vysis IntelliFISH | Protease and Hybridization Buffer | FISH | Oncological Disorders |
In 2025, the company expanded its molecular diagnostics portfolio by introducing new high-risk HPV and sexually transmitted infection (STI) assays for its Alinity m platform, and received regulatory accreditations for these tests, further broadening the scope of its diagnostic capabilities.
Further details on recent initiatives taken by Abbott and other molecular diagnostic companies have been provided in detail in the report.
Agilent Technologies Recently Launched 3 New Avida DNA Cancer Panels, based On Advanced NGS technology, Enabling Simultaneous DNA And Methylation Profiling From A Single Sample
2. Agilent Technologies
Agilent Technologies was established in 1999 as a spin-off from Hewlett-Packard. The company is a leading global provider specializing in life sciences, diagnostics, and applied chemical markets. The company’s broad portfolio includes advanced molecular diagnostics solutions that support accurate disease detection, biomarkers analysis, and personalized medicine. Its offerings are utilized by a broad range of customers, including academic institutions, clinical laboratories, pharmaceutical companies, biotechnology firms, and government agencies. With a commitment to quality and customer satisfaction, Agilent Technologies plays a crucial role in advancing research and development across multiple scientific disciplines, contributing to improvements in health, safety, and environmental sustainability.
Agilent Technologies: Company Details
| Key Parameters |
Specifications |
| Company Logo |  |
| Year of Establishment | 1999 |
| Number of Employees | 10,001+ |
| Headquarters |  |
Some of the molecular diagnostic solutions offered by Agilent have been mentioned below:
Agilent: Product Portfolio
| S. No. | Product Name | Solution Type | Technology | Diagnostic Applications |
| 1 | Artisan Link Pro | Staining System | Automated Slide Processing | Unspecified |
| 2 | Dako Omnis EBER RNA CISH | EBV & Kappa/Lambda Probes | CISH | Epstein-Barr Virus |
| 3 | EBV PNA Probe | EBV & Kappa/Lambda Probes | CISH | Latent Epstein-Barr Virus |
| 4 | SureFISH Probes | FISH Probes | FISH | Unspecified |
| 5 | Dako CoverStainer | Staining System | Hematoxylin and Eosin Staining | Unspecified |
| 6 | Autostainer Link 48 | Staining System | Immunohistochemistry | Unspecified |
| 7 | IQFISH Dako Omnis Panel | FISH Probes | FISH | Lung Cancer |
| 8 | IQFISH Dako Omnis Panel | FISH Probes | FISH | Lymphoma |
| 9 | Anti-FITC/AP CISH Accessory Kit | ISH Probes | ISH | Unspecified |
In April 2025, Agilent Technologies participated in American Association for Cancer Research with an intend to transform cancer research, diagnostics and therapeutics.
Further details on recent initiatives taken by Agilent Technologies and other molecular diagnostic companies have been provided in detail in the report.
BD leverages its Expertise in Molecular Diagnostics across Cancer Research and Infectious Disease Diagnostics to Establish as a Leader in the Industry
3. BD
BD is a leading global MedTech company that focuses on improving medical discovery, diagnostics, and the delivery of care. The solutions offered by the company play a crucial role in improving patient care enabling healthcare professionals to accurately diagnose diseases, administer treatments effectively, and improve patient safety. The company’s comprehensive range of products and services supports the range of healthcare applications, from diagnosis to treatment and recovery, which gives the company a vital edge in the global healthcare landscape.
BD: Company Overview
| Key Parameters |
Specifications |
| Company Logo |  |
| Year of Establishment | 1897 |
| Number of Employees | 10,000+ |
| Headquarters |  |
Some of the molecular diagnostic solutions offered by BD have been mentioned below:
BD: Product Portfolio
| S. No. | Product Name | Solution Type | Technology | Diagnostic Applications |
| 1 | BD MAX™ | Automated Nucleic Acid Extraction Device | PCR | Women's Health, STI, HAI, Infectious Diseases |
| 2 | BD MAX Vaginal Panel | Diagnostic Assay | PCR | Women's Health, STI |
| 3 | BD MAX CT/GC/T | Diagnostic Assay | PCR | Women's Health, STI |
| 4 | BD MAX GBS | Diagnostic Assay | PCR | Women's Health, STI |
| 5 | BD MAX Cdiff | Diagnostic Assay | PCR | HAI |
| 6 | BD MAX MRSA XT | Diagnostic Assay | PCR | HAI |
| 7 | BD MAX StaphSR | Diagnostic Assay | PCR | HAI |
| 8 | BD MAX Enteric Bacterial Panel | Diagnostic Assay | PCR | Gastrointestinal Diseases |
| 9 | BD MAX Extended Enteric Bacterial Panel | Diagnostic Assay | PCR | Gastrointestinal Diseases |
| 9 | BD MAX Enteric Parasite Panel | Diagnostic Assay | PCR | Gastrointestinal Diseases |
In 2025, BD announced the spin-off of its Biosciences and Diagnostic Solutions business from the rest of the company to empower focused innovation, accelerate growth opportunities, and maximize shareholder value.
Further details on recent initiatives taken by BD and other molecular diagnostic companies have been provided in detail in the report.
Danaher’s DxC 500i Clinical Analyzer Recently Received the USFDA Clearance, thereby, Supporting the Needs of Networked Laboratories
4. Danaher
Danaher is a global conglomerate which possesses a diverse portfolio of technology-driven companies that design, manufacture, and market innovative products and services to medical, industrial, and healthcare industry. The company's strategic acquisitions and investments in research and development are a testament to its growth and innovation across the overall healthcare domain. According to the company’s website, Danaher aims to address complex challenges in healthcare, environmental management, and industrial processes by delivering high-quality products and solutions.
Danaher: Company Overview
| Key Parameters |
Specifications |
| Company Logo |  |
| Year of Establishment | 1910 |
| Number of Employees | 10,000+ |
| Headquarters |  |
Some of the molecular diagnostic solutions offered by Cepheid (a wholly owned subsidiary of Danaher) have been mentioned below:
Danaher: Product Portfolio
| S. No. | Product Name | Solution Type | Technology | Diagnostic Applications |
| 1 | GeneXpert® II | 2-module Configuration Automated Cartridge-based NAAT System | NAAT | Infectious Diseases, Genetic Diseases, Respiratory Diseases, Oncological Disorders, Sexual Health, Women’s Health |
| 2 | GeneXpert Infinity | Automated Cartridge-based NAAT System | NAAT | Infectious Diseases, Genetic Diseases, Respiratory Diseases, Oncological Disorders, Sexual Health, Women’s Health |
| 3 | GeneXpert IV | 4-module Configuration Automated Cartridge-based NAAT System | NAAT | Infectious Diseases, Genetic Diseases, Respiratory Diseases, Oncological Disorders, Sexual Health, Women’s Health |
| 4 | GeneXpert XVI | 16-module Configuration Automated Cartridge-based NAAT System | NAAT | Infectious Diseases, Genetic Diseases, Respiratory Diseases, Oncological Disorders, Sexual Health, Women’s Health |
| 5 | Resistance Plus® MG FleXible | PCR Test | PCR | Sexually Transmitted Infections |
| 6 | Xpert® HIV-1 Viral Load | Qualitative real-time PCR test | Real-time PCR | Sexually Transmitted Infections |
| 7 | Xpert HPV | Qualitative real-time PCR test | Real-time PCR | Sexually Transmitted Infections |
| 8 | Xpert Norovirus | Qualitative real-time PCR test | Real-time PCR | Infectious Diseases |
| 9 | VXpert Xpress Strep A | Qualitative real-time PCR test | Real-time PCR | Respiratory Diseases |
| 9 | Xpertise | Process Management System | Laboratory Information System | Unspecified |
In early 2025, the company held a meeting of experts with a focus on the application of AI in improving human health. The importance of integration with physical workflows was underscored concerning diagnostic molecular testing innovation and precision.
Further details on recent initiatives taken by Danaher and other molecular diagnostic companies have been provided in detail in the report.
Thermo Fischer Scientific Presented its New Molecular Solutions in ESCMID Global 2025
5. Thermo Fisher Scientific
Thermo Fisher Scientific is engaged in providing analytical instruments, specialty diagnostics and life science solutions. In addition, the company offers instruments, equipment, software, services and consumables in order to cater to a number of healthcare challenges in various domains, such as pharmaceutical, biotechnology, industrial research, and clinical laboratory. The company’s product portfolio consists of laboratory supplies, laboratory equipment, laboratory instruments, chromatography instrumentation and mass spectrometry devices, clinical and diagnostics tools, cell culture materials, and molecular diagnostic solutions.
Thermo Fisher Scientific: Company Overview
| Key Parameters |
Specifications |
| Company Logo |  |
| Year of Establishment | 1956 |
| Number of Employees | 10,001+ |
| Headquarters |  |
Some of the molecular diagnostic solutions offered by Thermo Fisher Scientific have been mentioned below:
Thermo Fisher Scientific: Product Portfolio
| S. No. | Product Name | Solution Type | Technology | |
| 1 | QuantStudioTM 7 Pro Dx system | PCR System | Real Time PCR | |
| 2 | QuantStudio 5 Dx Real-Time PCR System | PCR System | Real Time PCR | |
| 3 | QuantStudio 5 Dx 10-Dye | Calibration Kit | Multiple-Dye Plate Calibration | |
| 4 | TaqPath DuraPlex 1-Step RT-qPCR Master Mix | Diagnostic Assay | Real Time PCR | |
| 5 | TaqPath BactoPure Microbial Detection Master Mix | Diagnostic Assay | Real Time PCR | |
| 6 | TaqPath ProAmp Master Mix | Diagnostic Assay | Real Time PCR | |
| 7 | TaqPath qPCR Master Mix | Diagnostic Assay | Real Time PCR |
Further details on recent initiatives taken by Thermo Fisher Scientific and other molecular diagnostic companies have been provided in detail in the report.
BioMérieux Recently Received the USFDA Approval for BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid
6. BioMérieux
BioMérieux is a global leader in molecular diagnostics segment which specializes in the development, manufacturing, and marketing of diagnostic solutions for clinical and industrial applications. According to the company website, it dedicates significant resources to research and development in order to advance diagnostic technologies. The company's products and solutions are widely used across the globe, with a presence in over 160 countries. The company collaborates with healthcare professionals, research institutions, and industrial partners to drive improvements in diagnostics and public health.
BioMérieux: Company Overview
| Key Parameters |
Specifications |
| Company Logo |  |
| Year of Establishment | 1963 |
| Number of Employees | 10,001+ |
| Headquarters |  |
Some of the molecular diagnostic solutions offered by BioMérieux have been mentioned below:
BioMérieux: Product Portfolio
| S. No. | Product Name | Solution Type | Technology | Diagnostic Applications |
| 1 | BIOFIRE FILMARRAY® TORCH® | Multiplex PCR System | PCR | Infectious Diseases |
| 2 | BIOFIRE® Respiratory Panel | Diagnostic Assay | PCR | Respiratory Infections |
| 3 | BIOFIRE Blood Culture Identification 2 | Diagnostic Assay | PCR | Hematological Diseases |
| 4 | BIOFIRE FILMARRAY Pneumonia Panels | Diagnostic Assay | PCR | Respiratory Infections |
| 5 | BIOFIRE FILMARRAY Meningitis / Encephalitis Panel | Diagnostic Assay | PCR | Neurological Disorders |
| 6 | BIOFIRE FILMARRAY Gastrointestinal Panel | Diagnostic Assay | PCR | Gastrointestinal Diseases |
| 7 | BIOFIRE SPOTFIRE® System | Multiplex PCR System | PCR | Infectious Diseases, Point-of-care Testing |
| 8 | BIOFIRE SPOTFIRE® Respiratory Panels | Diagnostic Assay | PCR | Respiratory Infections |
| 9 | EMAG® | Nucleic Acid Extraction System | Nucleic Acid Extraction | Hematological Diseases, Gastrointestinal Diseases, Respiratory Infections, Neurological Disorders |
In January 2025, BioMérieux acquired SpinChip Diagnostics, which is equipped with benchtop immunoassay diagnostics platform, strengthening its point-of-care testing portfolio. This acquisition enables BioMérieux to enhance rapid diagnostic testing capabilities, improve accuracy, and expand its market presence in decentralized healthcare settings.
Further details on recent initiatives taken by BioMérieux and other molecular diagnostic companies have been provided in detail in the report.
Grifols Initiated the Chronos-PD Research Program, Utilizing its Vast Repository of Over 100 Million Plasma Samples, and Cutting-edge Proteomics and AI Technology
7. Grifols
Grifols specializes in the production of plasma-derived medicines and transfusion medicines, contributing to the treatment of various chronic and rare diseases. The company claims to have a global presence in over 100 countries. According to the company’s website, Grifols boasts a comprehensive portfolio of plasma-derived therapies and diagnostic solutions which play a critical role in the diagnosis and treatment of various diseases. Additionally, the company claims to be one of the largest plasma collectors in the world, operating a network of donation centers.
Grifols: Company Overview
| Key Parameters |
Specifications |
| Company Logo |  |
| Year of Establishment | 1909 |
| Number of Employees | 10,001+ |
| Headquarters |  |
Some of the molecular diagnostic solutions offered by Grifols have been mentioned below:
Grifols: Product Portfolio
| S. No. | Product Name | Solution Type | Technology | Diagnostic Applications |
| 1 | BGG Navigator | Molecular Blood Group Genotyping | Blood | Hematologic Malignancies, Hemoglobinopathies, Sickle Cell Disease, Anemias |
| 2 | Blood Group Gene Sequencing | Gene Sequencing | Blood | RhD variants including weak D types 1,2,3,4 |
| 3 | Blood Group Gene Sequencing | Gene Sequencing | Blood | RhD zygosity |
| 4 | Blood Group Gene Sequencing | Gene Sequencing | Blood | RhCE variants |
| 5 | ABO Gene Sequencing | Gene Sequencing | Blood | ABO blood grouping discrepancies |
| 6 | Human Platelet Antigen Genotyping | Genotyping | Blood | HPA-1a/b |
| 7 | Human Platelet Antigen Genotyping | Genotyping | Blood | HPA-1, 2,3,4,5,6,9,15 |
| 8 | Human Platelet Antigen Genotyping | Genotyping | Blood | HPA Panel (1-11,15) |
In April 2025, Grifols announced its partnership with IBL International with an intent to develop advanced biomarker panels for a new, highly sensitive multiplex immunoassay platform using single molecule counting (SMC) technology.
Further details on recent initiatives taken by Grifols and other molecular diagnostic companies have been provided in detail in the report.
Roche received FDA Breakthrough Device Designation for VENTANA® TROP2 (EPR20043) RxDx Device, the First AI-based Computational Pathology CDx for NSCLC
8.Roche
Roche is a global leader in the molecular diagnostics domain which provides a wide range of products and services for disease detection, disease monitoring, and patient management. The company offers diagnostic solutions intended to be used worldwide in hospitals, reference laboratories, physician offices, and clinics aiming to enhance the ability to diagnose and treat diseases effectively. The company offers comprehensive diagnostic portfolio which plays a critical role in improving patient care, advancing medical research, and promoting public health.
Roche: Company Overview
| Key Parameters |
Specifications |
| Company Logo |  |
| Year of Establishment | 1834 |
| Number of Employees | 10,001+ |
| Headquarters |  |
Some of the molecular diagnostic solutions offered by Roche have been mentioned below:
Roche: Product Portfolio
| S. No. | Product Name | Solution Type | Technology | Diagnostic Applications |
| 1 | Cobas® eplex system | Molecular Diagnostics Analyzer | Nucleic Acid Detection | Infectious Diseases |
| 2 | cobas prime pre-analytical system | Pre-analytical System | Nucleic Acid Detection | Unspecified |
| 3 | cobas 5800 System | PCR-based NAT System | PCR | Infectious Diseases, Respiratory Diseases, Sexual Health |
| 4 | Digital LightCycler® System | Digital PCR System | PCR | Oncological Disorders |
| 5 | MagNA Pure 24 System | Clinical Sample Extractor | Magnetic Bead Technology | Infectious Diseases |
| 6 | LightCycler® PRO System | qPCR system | qPCR | Cardiovascular Diseases, Gastrointestinal Diseases, Women's Health, Hematological Diseases, Infectious Diseases, Respiratory Infections |
| 7 | MagNA Pure 96 System | Automated Nucleic Acid Purification System | Magnetic Glass Particle Technology | Unspecified |
| 8 | cobas 8800 System | PCR-based NAT System | PCR | Women's Health, Infectious Diseases, Respiratory Infections |
| 9 | cobas 201 system | Multi-dye NAT Screening System | Real Time PCR | Infectious Diseases |
| 9 | cobas 4800 system | Nucleic Acid Amplification and Isolation System | Real Time PCR | Women's Health, Infectious Diseases, Respiratory Infections |
In February 2025, Roche introduced its proprietary Sequencing by Expansion (SBX) technology-a new generation of next-generation sequencing that integrates novel chemistry with an advanced sensor module to deliver ultra-rapid, high-throughput sequencing, offering exceptional flexibility and scalability for a broad range of applications.
Further details on recent initiatives taken by Roche and other molecular diagnostic companies have been provided in detail in the report.
Siemens Healthineers is Actively Developing a Next-generation, High-throughput Molecular Diagnostics (MDx) Platform Designed to Deliver Greater Automation, Flexibility, and Affordability
9. Siemens Healthineers
Siemens Healthineers, a healthcare division of Siemens AG, specializes in providing imaging, diagnostics, and advanced therapeutic solutions. The company is engaged in providing advanced diagnostic solutions, catering to both medical professionals and consumers. The company boasts its presence in over 70 countries, and claims to offer high-quality, reliable, and cost-effective medical technologies to support healthcare systems worldwide. The company’s comprehensive portfolio includes diagnostic imaging, laboratory diagnostic solutions, digital health solutions, minimally invasive procedures and surgical robots.
Siemens Healthineers: Company Overview
| Key Parameters |
Specifications |
| Company Logo |  |
| Year of Establishment | 1896 |
| Number of Employees | 10,001+ |
| Headquarters |  |
Some of the molecular diagnostic solutions offered by Siemens Healthineers have been mentioned below:
Siemens Healthineers: Product Portfolio
| S. No. | Product Name | Solution Type | Technology | Diagnostic Applications |
| 1 | VERSANT® HCV Auto LiPA 48 | Genotyping System | Automated Strip Processing System | Kidney Diseases |
| 2 | VERSANT AutoBlot 3000H | Genotyping System | Automated Strip Processing System | Kidney Diseases |
| 3 | VERSANT HCV Genotype 2.0 Assay | Genotyping Assay | Reverse-hybridization Technology | Kidney Diseases |
| 4 | VERSANT kPCR Molecular System SP | Automated Nucleic Acid Extraction System | Automated PCR Technology | Respiratory Infections |
| 5 | VERSANT kPCR Molecular System AD | PCR Cycling System | Automated PCR Technology | Respiratory Infections |
| 6 | VERSANT Sample Preparation 1.0 | Reagents Kit | Magnetic Particles Extraction | Unspecified |
| 7 | FTD SARS-CoV-2 Assay | Diagnostic Assay | Single-Well Dual Target Assay | Respiratory Infections |
In March 2025, the company entered into a 8-year deal the Canada government for the upgradation and replacement of cancer-specific diagnostic imaging equipment.
Further details on recent initiatives taken by Siemens Healthineers and other molecular diagnostic companies have been provided in detail in the report.
Sysmex Showcased its Latest Laboratory Innovations and Technologies in the Medlab Middle East 2025
10. Sysmex
Sysmex is engaged in distributing and supporting automated molecular diagnostic solutions. The company offers a variety of solutions, including hematology analyzers, flow cytometry, diagnostic technology solutions, coagulation and urinalysis analyzers, diagnostic reagents and information systems. The company has subsidiaries in several regions, such as North America, Europe, Middle East and Asia Pacific. In addition, the company is engaged in the development, manufacture, import and export of diagnostic instruments, reagents and software.
Sysmex: Company Overview
| Key Parameters |
Specifications |
| Company Logo |  |
| Year of Establishment | 1919 |
| Number of Employees | 10,001+ |
| Headquarters |  |
Some of the molecular diagnostic solutions offered by Sysmex have been mentioned below:
Sysmex: Product Portfolio
| S. No. | Product Name | Solution Type | Technology | Diagnostic Applications |
| 1 | RD-210 | Gene Amplification Detector | Reverse Transcriptase Loop-Mediated Isothermal Amplification | Oncological Disorders |
| 2 | RP-10 | Pre-treatment Homogenization System | Homogenization | Oncological Disorders |
| 3 | Lynoamp CK19 E | Cytokeratin 19 Carcinoma Marker | mRNA expression | Oncological Disorders |
In April 2025, Sysmex began full-scale operations at its new manufacturing base in Sanand II Industrial Estate, Gujarat, India. This facility, the Group’s first capable of producing both diagnostic reagents and instruments, supports the “Make in India” initiative and currently manufactures products including the XQ™-Series Automated Hematology Analyzer (XQ-320), with plans to expand its production lineup and strengthen supply capacity for the growing Indian market
Further details on recent initiatives taken by Sysmex and other molecular diagnostic companies have been provided in detail in the report.
What About the Other Molecular Diagnostic Companies Around the World?
The above presentation features 10 top molecular diagnostic companies selected from a pool of key players that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.
About Author
Shreeya_Agrawal
I am Shreeya Agrawal, an Associate at Roots Analysis since 2021, with a Master’s degree in Biotechnology (Integrated M.Tech) from Jaypee University of Information Technology. My educational foundation has enabled me to understand technological advancements in the pharmaceutical industry and provide comprehensive insights through syndicate reports and consulting. I have worked with various pharmaceutical companies, leveraging my expertise to deliver valuable insights and strategic guidance. Committed to staying abreast of the latest developments and regulatory changes in the dynamic pharmaceutical landscape, I am passionate about the transformative role of data analytics in decision-making. By analyzing data, I identify hidden patterns and opportunities, supporting pharmaceutical companies in achieving success through knowledge-driven, innovative solutions.
Sources
- https://extranet.who.int/prequal/news/new-hpv-assay-prequalified-who
- https://www.investor.agilent.com/news-and-events/news/news-details/2025/Agilent-Showcases-Solutions-and-Partnerships-Transforming-Cancer-Research-and-Therapeutics-at-AACR-2025/default.aspx
- https://investors.bd.com/news-events/press-releases/detail/875/bd-announces-intent-to-separate-biosciences-and-diagnostic-solutions-business-to-enhance-focus-drive-growth-and-unlock-value
- https://www.genengnews.com/gen-edge/from-promise-to-practice-danaher-gathers-visionaries-to-discuss-ai-driven-rd/
- https://www.biomerieux.com/corp/en/journalists/press-releases/acquisition-SpinChip-immunoassay.html
- https://www.grifols.com/en/view-news/-/news/grifols-partners-with-ibl-international-to-develop-advanced-biomarker-panels-for-unique-clinical-diagnostics-platform
- https://www.nasdaq.com/press-release/roche-unveils-new-class-next-generation-sequencing-its-novel-sequencing-expansion
- https://www.auntminnie.com/clinical-news/molecular-imaging/article/15741016/siemens-healthineers-canadian-province-siemens-begin-diagnostic-imaging-enhancement-program
- https://www.sysmex.co.jp/en/news/2024/240801.html
Published Date Category Pharmaceutical and Biotech Healthcare IT Life Sciences and Bioprocessing Medical Devices and Diagnostics Abstract by Abstract Link Report Meta Tags Meta Title Meta Description Meta Description Meta Keywords Meta Keywords Formatting applied